Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

NCT04095858 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Hematopoietic Stem Cell Transplantation
Acute Graft Versus Host Disease
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Efprezimod alfa
DRUG: Placebo
DRUG: Methotrexate
DRUG: Tacrolimus

Sponsor

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)